Tioga Novel Therapies
Novel Therapies for the Treatment of Gastrointestinal Diseases
Tioga Pharmaceuticals Latest News

Tioga Pharmaceuticals, Inc. Raises $10 Million to Advance Phase 3 Clinical Development of Asimadoline in Irritable Bowel Syndrome

Tioga Pharmaceuticals, Inc. today announced the closing of a $10 million Series B equity financing led by new investor Thomas, McNerney & Partners, which invested $8 million in the round ...more 
Tioga product asimadoline
Tioga's lead product is asimadoline, a proprietary, peripherally restricted small molecule kappa opioid agonist, originally discovered by Merck KGaA of Darmstadt, Germany.
Asimadoline is currently in Phase 3 clinical development for the treatment of irritable bowel syndrome (IBS) ...more
The Disease
IBS is a common condition that is found in high prevalence throughout the world. Affected patients experience recurrent episodes of abdominal pain or discomfort associated with a change in bowel pattern ...more